



TOGETHER
for a sustainable future

OCCASION

This publication has been made available to the public on the occasion of the 50th anniversary of the United Nations Industrial Development Organisation.



TOGETHER
for a sustainable future

DISCLAIMER

This document has been produced without formal United Nations editing. The designations employed and the presentation of the material in this document do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations Industrial Development Organization (UNIDO) concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries, or its economic system or degree of development. Designations such as “developed”, “industrialized” and “developing” are intended for statistical convenience and do not necessarily express a judgment about the stage reached by a particular country or area in the development process. Mention of firm names or commercial products does not constitute an endorsement by UNIDO.

FAIR USE POLICY

Any part of this publication may be quoted and referenced for educational and research purposes without additional permission from UNIDO. However, those who make use of quoting and referencing this publication are requested to follow the Fair Use Policy of giving due credit to UNIDO.

CONTACT

Please contact publications@unido.org for further information concerning UNIDO publications.

For more information about UNIDO, please visit us at www.unido.org



08914



Distr.
LIMITED

ID/WG.300/5
23 May 1979

ENGLISH

United Nations Industrial Development Organization

Regional Seminar on Industrial Application
of Microbiology in the Pharmaceutical Industry,
Havana, Cuba, - 9 July 1979

THE FERMENTATION PROCESS AND PRODUCTION OF GENTAMICIN C
AN AMINOGLYCOSIDE ANTIBIOTIC COMPLEX *

by

J. Gyimesi**

* The views expressed in this paper are those of the author and do not necessarily reflect the views of the secretariat of UNIDO. This document has been reproduced without formal editing.

** Institute for Drug Research, Budapest, Hungary.

Aminoglycosides represent a group of antibiotics of major importance. Recently, an ever increasing number of these antimicrobial agents /e.g. streptomycin, neomycin, kanamycins, paromomycin, gentamicins, tobramycin, sisomicin, etc./ and their semisynthetic derivatives /e.g. amikacin, dibekacin, etc./ obtained by chemical modification have been introduced into human therapy. In addition, this type of antibiotics have found application in agriculture, too. Discoveries of new aminoglycosides either by conventional soil screening, by chemical modification of known aminoglycosides or by mutational biosynthesis /hybrimycins/ are needed to circumvent inherent toxicity problems and control the infections caused by cultures resistant to streptomycin, kanamycin, etc.

A detailed review by Price, Godfrey and Kawaguchi shows the structure-activity relationships of aminoglycosides containing 2-deoxystreptamine. The review of Takashi Nara gives also a good summary of recent advances in this field.

The sale of aminoglycosides over the world in 1977 is represented by the sum of 350 million £.

The gentamicin complex produced by various *Micromonospora* species was first described by Weinstein, Luedemann, Oden and Wagman in 1963. The main components of the gentamicin

complex are gentamicins C₁, C₂ and C_{1a} used widely in clinical practice. The gentamicin C complex is bactericidal and has greater antibacterial activity than streptomycin, neomycin or kanamycins. It is effective against many strains of Gram-negative bacteria including species of Escherichia, Enterobacter, Klebsiella, Salmonella, Serratia, Shigella, some Proteus and against Pseudomonas aeruginosa. Minimum inhibitory concentrations have been reported to range from 0.06 to 8 mcg per ml.

Among the Gram-positive organisms Staphylococcus aureus is highly sensitive to gentamicin with minimum inhibitory concentrations, being reported within the range of 0.125 to 1 mcg per ml. Other Gram-positive cocci are less sensitive, but Bacillus Clostridium and Corynebacterium spp. may be inhibited by normal concentrations. Gentamicin sulfate is used to treat septicaemia and other severe systemic infections due to sensitive Gram-negative organisms. In the treatment of urinary-tract infections with gentamicin, alkalis should be given to raise the urinary pH above 7. The usual dose of gentamicin given intramuscularly is 400 to 800 mcg per kg body weight in every 8 hours. Gentamicin has been given intravenously in the same doses that are used intramuscularly. The course of treatment should generally be limited to 7 days. Gentamicin is poorly absorbed from the gastro-intestinal tract. If symptoms of ototoxicity occur, gentamicin should be withdrawn immediately. It

should be given with care and in reduced dosage to patients with impaired renal function.

Gentamicin C complex is being produced in Hungary since 1974. The producing strain is *Micromonospora purpurea* var. *nigrescens nova varietas*, isolated from soil in 1970, marked as X-148. This *Actinomyces* strain has been assigned accession number MNG 00112 in the Hungarian National Culture Collection. Table 1 below sets forth the comparison of strain X-148 with those of *M. purpurea* /NRRL-2953/ and *M. purpurea* var. *violacea* 55-5829 /accession number: Coll. Microb. Bulg., DKILS, 55/3 III. 1971/.

Table 1

Characteristic	M. purpurea /NRRL-2953/	K-148 /MNG 00112/	M. purpurea var. violacea 55-5829
Macro-morphology	No aerial mycelium, colonies are raised, spiral, abundant growth, waxy. Surface color: terracotta to brownish. Reverse: russet to deep brown. No soluble pigment.	No aerial mycelium, raised colonies but sink into the medium, waxy, slightly dry surface, very poor growth. Color: blackish deep purple. No soluble pigment.	No aerial mycelium, abundant growth, irregularly shaped, smooth colonies. Microscopically the surface is wrinkled, waxy, the radial ditches form strings which get smoothed in time. Colonies: violet.
Micro-morphology	Hyphae are long and branching, regular, not shaped, diameter: 0.5 μ . Spores are formed at the end of single sporophores, either round- or ellipsoidal-shaped, diameter: 1.0 μ .	Hyphae are long and extensively branching, diameter: 0.6-0.7 μ . Conidia are rare and round-shaped and smooth. Diameter: 1.0-1.3 μ , no sporophores.	On the young hyphae, unicellular spores are formed which are oval-shaped, diameter: 1.0 μ . On liquid medium hyphae are fine and completely basophil in star like position.
Gelatin	Weak liquefaction	Liquefaction	Liquefaction
Sucrose	Inverted	Slightly inverted	Inverted
Starch	Hydrolyzed	Hydrolyzed	Hydrolyzed
Cellulose	Slightly decomposing	Slightly decomposing	
Glucose-asparagine agar	Good growth, from bright peach to medium red orange color.	Very poor growth, blackish purple color.	
Tyrosine agar	Good growth, no soluble pigment.	A very slow growth only at 37°C, little tan color, soluble pigment.	Cream color, darker in the middle.

Table 2

Carbohydrate utilization

Carbohydrate	M. purpurea /NRRL-2953/	X-148 /MNG 00112/	M. purpurea var. violacea 55-5829
D-glucose	+	+	+
D-galactose	+	-	+
Sucrose	+	+	+
Maltose	0	+	+
Lactose	-	-	+
Raffinose	-	-	+
Sorbose	0	-	0
Cellulose	0	+	0
Trehalose	0	(+)	0
Melibiose	0	-	0
Melicitose	0	(+)	0
Glycerol	0	-	-
Sorbitol	-	-	-
Starch, soluble	+	+	+
D-xylose	+	+	+
L-Arbinose	+	+	-
L-rhamnose	-	+	-
Galactitol	0	-	+
D-mannitol	-	-	-
Inositol	-	-	-
Salicin	0	-	0
α -methyl-D-glucoside	0	-	0
Fructose	-	0	-
Mannose	+	0	0
Cellulose	-	+	0
Dextrin	0	0	+

Based on the considerably differing characteristics the strain X-148 can be precisely distinguished from the following species or variants of *Micromonospora* strains producing gentamicins or gentamicin-type antibiotics:

Micromonospora purpurea NRRL-2953

Micromonospora purpurea var. *violacea* 55-5829

Micromonospora echinospora NRRL-2985

Micromonospora echinospora var. *ferruginea* NRRL-2995

Micromonospora echinospora var. *pallida* NRRL-2996

Micromonospora grisea NRRL-3800

Micromonospora rhodorangea NRRL-5326

Micromonospora inyoensis NRRL-3292

On the basis of the above, the new strain X-148 was designated as *Micromonospora purpurea* var. *nigrescens* nov. var. Description of the applied X-148 strain according to Waksman's system is given below:

Morphology:

Very slow growth. Colonies resemble to bacterial ones, with slightly dry surface and unbroken edges, as a rule, slightly raised from the nutrient agar but at the same time sink into it. Owing to non-diffusing pigment they have a blackish-purple color. Aerial mycelium is not formed. Microscopically, hyphae are long and extensively branched, diameter: 0.6-0.7 μ . Conidia (spores) rarely discernible on the hyphae, are round-shaped and smooth, diameter: 1.0-1.3 μ . No sporophores.

Biochemical, physical properties:

Nurtient agar: no growth

Glucose-asparagine agar: colonies are grown very poorly, surface is dry, slightly raised, stick into the agar, with unbroken edges, blackish-purple color.

Tyrosine agar: no growth at 26°C, very slow growth at 37°C, colonies are bright purple, slight tan color pigment diffusing into the agar.

Corn-meal agar: slow growth, similarly to that observed on glucose-asparagine agar.

Blood agar: color of colonies: grayish-pink, no haemolysis.

Löffler's serum-medium: colonies are meat-colored, strong proteolysis is observable.

Cellulose: poor growth.

NaCl-tolerance: 3.5 % /on glucose-yeast-extract agar/.

Gelatin: liquefaction.

I. Preservation of the gentamicin producing Micromonospora strain

1./ For the preservation of the strain bouillon agar slant pH 7.2, adjusted with 0.5 % peptone and 0.5 % NaCl is used. Slant cultures are incubated at 37°C for one day /in the case of inoculation from shake flask culture/ and 3-5 days /in the case of inoculation from a single colony/, respectively, then stored at 4° - 10°C. Under these conditions the producing capacity of the strain is generally preserved.

2./ The strain sporulated vary poorly on the different media tested by us. Its producing capacity can be preserved, however, for a period of one year by means of lyophilizing a vegetative seed culture.

3./ At -15°C the strain can be preserved at least for 3 months. For this purpose the following medium is inoculated with agar slant culture:

0.3 % beef extract
0.1 % peptone
0.1 % sucrose
2.4 % starch, soluble
0.4 % CaCO_3

with tap water, pH 7.0 before sterilization. The medium is sterilized at 121°C for 20 min.

A 200 ml volume is shaken in a 500 ml Erlenmeyer flask for 2-3 days at 37°C , followed by a dition of 3 % glycerol and freezing in mixture of acetone- CO_2 .

II. Preservation and checking of the producing capacity

1./ The most successful way for preservation of the productivity is as follows:

The deep-frozen vegetative culture is plated onto bouillon-agar, pH 7.2. After incubation for 4 days at 37°C , inoculation onto agar slants of the same composition by means of individual colonies is carried out. After a further 4 days incubation at 37°C , the culture is inoculated into 500 ml Erlenmeyer flasks with 100 ml working volume, using three parallels, having the following composition:

3.0 % soya meal
1.5 % starch
0.4 % CaCO₃
2 mcg/ml CoCl₂.6H₂O

with tap water, pH 7.0-7.5 before sterilization. Sterilization is performed at 121°C for 20 min.

Incubation is at 37°C on a rotary shaker /320 r.p.m., 37 mm stroke/. From the 3-days-old cultures sterile samples are taken and kept at 4-10°C for a further 4 days. In the meantime, productivity of cultures are checked and, from the correspondingly stored culture having the highest producing capacity, inoculation is performed onto bouillon slant, pH 7.2. After incubation at 37°C for one day seed cultures are inoculated again from the slant for freezing purposes using the method described under I/3.

2./ Checking of the production is carried out on the following medium:

In 500 ml Erlenmeyer flasks of 100 ml working volume

3.0 % soya meal
1.5 % potato starch
0.4 % CaCO₃
2 mcg/ml CoCl₂.6H₂O

dissolved in tap water, pH 7.0-7.5, sterilization at 121°C for 20 min.

Media are inoculated with 1 ml of suspension made from agar slant or deep freezeed vegetative culture, respectively, and shaken at 28°C on a rotary shaker /320 r.p.m., 37 mm stroke/.

Production, sterility and morphology are first checked at the age of 72 h and as a rule for a further three days.

3./ For a 72-hour-old culture, dense mycelium of thin slightly wavy hyphae is characteristic. In the 72th-96th hours slight sporulation starts, which gets increased by age. No considerable fragmentation is observable.

4./ pH of the culture from the initial 7.0 decreases by 0.5-1 unit, then is generally increased to 8.0-8.2 at the 144th h.

5./ Average production development:

Inoculated with agar slant culture:

72 h	200-300 mcg/ml
96 "	300-400 "
120 "	400-500 "
144 "	500-600 "

Inoculated with deep freezeed vegetative culture:

72 h	200-250 mcg/ml
96 "	250-350 "
120 "	350-450 "
144 "	450-500 "

6./ Average component composition of the complex, determined from a gentamicin C complex, prepared from a 144 hours fermentation broth: /crude substance/

C _{1a}	19 %
C ₂	45 %
C ₁	36 %

III. Preparation of seed culture

1./ For preparation of seed culture deep freezed vegetative inoculum not older than three months is used. Composition of the medium:

0.3 % beef extract
0.1 % peptone
0.1 % sucrose
2.4 % starch, soluble
0.5 % yeast extract
0.4 % CaCO_3

tap water, pH 7.0.

200 ml medium is prepared in 500 ml Erlenmeyer flasks, sterilization at 121°C for 20 min.

2./ Three flasks containing 200 ml medium are inoculated with 1-1 ml seed and shaken for 48-72 h at 37°C . After microscopical checking 500 ml inoculum is used to inoculate 5 l medium.

3./ Microscopic characteristics of a 72-hour-old culture: colonies consist of thin, slightly wavy mycelia, not forming a continuous network. Slight spore formation, no fragmentation.

IV. Fermentation process

The culture thus obtained was used to inoculate 2000 liters of the sterilized medium in a 3 cubic meter fermentation tank having the following composition /grams/liter/

Potato starch	10 g
sucrose	5 "
yeast extract	5 ml /10 % solution/
casein hydrolyzate	20 " /20 % " /
peptone	2 g
corn steep liquor	1 " /50 % dry weight/
CaCO ₃	4 "
palm oil	2 ml
tap water	

pH 7.0 before sterilization. The inoculated medium is aerated at a rate of 1/1 v/v and stirred 130 r.p.m. at 35°C for 50-60 h. The resulting culture is then used to inoculate the 30 cubic meter producing tank fermentor having 20 cubic meter of the following composition

/grams/liter/

soya meal	30 g
potato starch	15 "
glycerol	15 ml
CaCO ₃	5 g
CoCl ₂ .6H ₂ O	2 mg
palm oil	2 g
tap water	

pH 7.0 before sterilization. Sterilization is carried out while stirring at 121°C for 1 h. Fermentation is carried out in acid-fast steel tanks. Rate of stirring is 130 r.p.m. and aerated at 1/1 v/v.

Antibiotic production starts in the 35-40th h and highest value is reached by 100-110 h.

Total antibiotic activity of the broth referred to gentamicin-C standard is 850 U/ml / 1 U is equal to 1 mcg gentamicin standard; C_1 : 32%, C_2 : 48%, C_{1a} : 20%, determined on Staphylococcus epidermidis test organism by large plate agar diffusion method. The total amount of antibiotics produced is 1000-1050 mcg/ml from which 75% is gentamicin-C. The composition of gentamicin-C fraction: $C_1=36\%$, $C_2=45\%$, $C_{1a}=19\%$.

Fermentations carried out were batch fermentations, we have not any experience regarding semi-continuous fermentation. Economical requirements, of course, improve by raising the volume of the fermentors. We could attain economical production already in 30 cubic meter volume, though a 100 cubic meter volume would be economically more advantageous. Regarding automation, it is worth at least to automatize temperature, pH and addition of anti-foam agents.

The raw materials of the fermentation process listed above being agro-industrial products are practically locally available. As for sources of supply for the equipment: for fermentation of gentamicin no special requirements are needed, they might be purchased anywhere.

The anticipated losses due to contamination in case of trained work are around 5%.

Isolation of crude gentamicin complex

To 1 cubic meter of the fermentation broth /850 mcg/ml/ produced by the above process, 5 N sulfuric acid was added at 20°C to adjust the pH to 2.0. The broth was filtered and the mycolial cake washed by 0.1 volume of tap water giving 920 l filtrate. To this filtrate, 2.7 kg oxalic acid was added, furthermore, the pH was adjusted to 7.5 by sodium hydroxyde solution. After 10 min heating at 80-90°C the broth was filtered and the mycelial cake washed with 50 l tap water. The 980 l /825 mcg/ml/ solution obtained was passed through a 3-column-resin-system at room temperature, each column /8x60 cm/ containing 3-3 l carboxyl-type cation exchange resin /Wofatit CP-300/ in Na form. Flow rate 50 l/h. During the absorption process the first column was practically saturated i.e. an effluent containing 800 mcg/ml activity was obtained. About 15 % of the total antibiotic activity was absorbed on the second column. The effluent of this column contained only 5 - 10 mcg/ml at the end of the absorption process. In case of continuous processing, this column was employed further for absorption of active broth. The first column was washed with 25 l distilled water then antibiotics were eluted with 4 N sulfuric acid at a flow rate of 0.5 l/h. The effluent fractions con

taining more than 5000 mcg/ml were pooled, yielding 4500 ml solution of 130,000 mcg/ml activity.

/By batch process, from the second and third columns 3500 ml 40,000 mcg/ml and 2600 ml 15,000 mcg/ml eluates were obtained by a similar way./

The pH of the dark brown, acidic eluate obtained from the first column was adjusted to 4.5 by stirring with triethyl amine then methanol was given /about 2500 ml/ to the solution until the turbidity was just disappearing. To the solution activated charcoal was added and after 30 min stirring, it was filtered. The carbon was washed by distilled water resulting 6900 ml solution with 83,000 mcg/ml activity. This solution was pured while continuous stirring into 35 l methanol. The precipitated crude gentamicin was filtered, washed twice with methanol and dried in vacuo at 30-40°C. By this way 962 grams of antibiotic complex were obtained as sulfate salt, assaying at 536 mcg/mg, ash content: 2.0 %, rotation: $[\alpha]_D^{25} = +104^\circ / 1.0 \%$ in water/.

By batch process, the sulfuric acid eluates obtained from the second and third columns by a similar way yield a further 108 g of crude sulfate salt having 536 mcg/mg activity. Total yield: 1130 g crude gentamicin sulfate.

Isolation of components

The crude gentamicin complex /500 g which corresponds to 670 g of crude sulfate salt above/ was chromatographed at first on Amberlite CG-50 Type-I resin developed with increasing concentration of ^{aqu} ammonia. The pattern of chromatography is shown in Fig. 1. The antibiotic complex was separated into seven mixtures indicated on Table 3.

Table 3. Chromatographic separation of crude gentamicin

Fractions	Antibiotic mixtures	Main component(s)	Weight (g)
6 ~ 30	I	Compound I-1	24.2
31 ~ 91	II	Gentamicin A, antibiotic G-418, compound II-2	49.8
92 ~ 123	III	garamic, gentamicin A ₁	17.1
124 ~ 175	IV	gentamicin B, B ₁	18.6
176 ~ 198	V	sisomicin	17.3
199 ~ 260	VI	gentamicin C ₁ , C ₂ , C ₃	345.5
261 ~ 298	VII	gentamicin C ₂	16.2

Fig. 1. Chromatographic separation of gentamicin components. Weights and Rf values of components.
* (TLC, system B)


Resin: Amberlite CG-50 I (100 ~ 200 mesh)

Column: 12 x 120 cm

Sample: 500 g crude gentamicin

Elution: 30 ~ 30 liters of 0.05, 0.10, 0.12, 0.14, 0.16, 0.18, 0.20, 0.25, 0.30 and 0.50 N ammonium hydroxide

Fractions: 1,000 ml




Chromatographic analysis by systems A, B and C of the I-VII mixtures indicate their complex nature. There are more or less overlapping between mixtures and each of them contains 4~12 components. The bioautographic detection showed that all of the components, except components I-1 and III-2, have bioactivity against *B. subtilis*. Application of the stepwise gradient elution method resulted in a good resolution of substances having different structural features but similar polarity. The proper combination of various ion-exchange chromatographic procedures enabled the separation of 35 pure components of the gentamicin complex.


Table 4. Physical and chemical properties of gentamicin minor components

Structure	Compound number	Identical	Formula	MW	[α] _D ²⁰ (1% water)	PC		TLC	
						RI rel. B, System A	RI System B	RI System C	
1	I-1	New compound	C ₂₀ H ₃₀ N ₄ O ₇	444	144°	1.60	0.93	0.16	
2	I-2	Gentamicin A ₁	C ₁₇ H ₂₃ N ₄ O ₁₁	455	138°	0.25	0.08	0.47	
3	II-1	G-418	C ₂₀ H ₃₀ N ₄ O ₁₀	496	168°	0.73	0.27	0.60	
4	II-2	New compound	C ₁₈ H ₂₆ N ₄ O ₁₀	482	140°	0.52	0.15	0.73	
5	II-3	Gentamicin X ₂	C ₁₈ H ₂₆ N ₄ O ₁₀	482	158°	0.56	0.16	0.66	
6	II-4	Gentamicin A	C ₁₈ H ₂₆ N ₄ O ₁₀	468	146°	0.36	0.08	0.84	
7	III-1	New compound	C ₁₉ H ₂₇ N ₄ O ₁₀	482	156°	0.46	0.18	0.67	
8	III-2	Garamine	C ₁₈ H ₂₇ N ₄ O ₈	321	137°	0.91	0.31	0.74	
9	III-3	Gentamicin A ₁	C ₁₈ H ₂₆ N ₄ O ₁₀	468	167°	0.37	0.09	0.82	
10	IV-1	Gentamicin B	C ₁₈ H ₂₆ N ₄ O ₁₀	482	155°	0.41	0.15	0.79	
11	IV-2	Gentamicin B ₁	C ₁₈ H ₂₆ N ₄ O ₁₀	496	163°	1.00	0.23	0.62	
12	IV-3	J1-20A	C ₁₈ H ₂₆ N ₄ O ₈	481		0.39	0.14	0.76	
13	IV-4	J1-20B	C ₂₀ H ₃₀ N ₄ O ₇	495	150°	0.94	0.25	0.46	
14	V-1	Sisomicin	C ₁₉ H ₂₇ N ₄ O ₇	447	188°	0.86	0.60	0.24	
15	V-2	New compound	C ₁₈ H ₂₆ N ₄ O ₇	449	156°	0.75	0.56	0.19	
16	V-3	Gentamicin A ₂	C ₁₈ H ₂₆ N ₄ O ₁₀	468	166°	0.29	0.06	0.84	
17	VII-1	New compound	C ₁₈ H ₂₆ N ₄ O ₇	463	142°	1.13	0.69	0.13	
18	VII-2	Gentamine C ₁	C ₁₇ H ₂₃ N ₄ O ₄	318	88°	1.35	0.73	0.19	
19	VII-3	New compound	C ₁₇ H ₂₃ N ₄ O ₇	449	148°	0.92	0.55	0.17	
20	VII-4	Gentamine C ₂	C ₁₇ H ₂₃ N ₄ O ₄	304	92°	1.12	0.59	0.27	
21	VII-5	New compound	C ₁₈ H ₂₇ N ₄ O ₇	435	144°	0.71	0.48	0.20	
22	VII-6	Gentamine C ₁	C ₁₇ H ₂₃ N ₄ O ₄	290	97°	0.82	0.42	0.28	

Fig. 2. Structures of compounds



	R ₁	R	R	R ₁	R ₂	R	R
2	H	OH	NH ₂	OH	H	OH	OH
3	CH ₃	OH	NH ₂	OH	OH	CH ₃	NHCH ₃
4	CH ₃	OH	NH ₂	OH	H	OH	NHCH ₃
5	H	OH	NH ₂	OH	OH	CH ₃	NHCH ₃
6	H	OH	NH ₂	OH	H	OH	NHCH ₃
7	CH ₃	OH	NH ₂	OH	OH	H	NHCH ₃
9	H	OH	NH ₂	OH	OH	H	NHCH ₃
10	H	NH ₂	OH	OH	OH	CH ₃	NHCH ₃
11	CH ₃	NH ₂	OH	OH	OH	CH ₃	NHCH ₃
12	H	NH ₂	NH ₂	OH	OH	CH ₃	NHCH ₃
13	CH ₃	NH ₂	NH ₂	OH	OH	CH ₃	NHCH ₃
15	CH ₃	NH ₂	NH ₂	H	OH	CH ₃	NH ₂
16	H	NH ₂	OH	OH	OH	H	NHCH ₃
17	CH ₃	NHCH ₃	NH ₂	H	OH	H	NHCH ₃
19	CH ₃	NH ₂	NH ₂	H	OH	H	NHCH ₃
21	H	NH ₂	NH ₂	H	OH	H	NHCH ₃



	R ₁	R ₂	R ₃
(18)	CH ₃	NHCH ₃	H
(20)	CH ₃	NH ₂	H
(22)	H	NH ₂	H
(25)	H	OH	OH
(26)	CH ₃	OH	OH
(29)	H	NH ₂	OH
(30)	CH ₃	NH ₂	OH

	R ₁	R ₂
(24)	OH	CH ₃
(27)	H	OH
(28)	OH	H

Mixture I: The relatively apolar compound I-1 was separated from compound I-2 /gentamicin A₂/ on QAE-Sephadex column with water as eluent. Compound I-1 was eluted first and it was purified by repeated ion-exclusion chromatography of Dowex 1-X2 resin. Gentamicin A₂ was isolated from the later fractions by chromatography on CM-Sephadex eluted with 0.05, 0.07 and 0.10 N ammonium hydroxide, successively. Crude gentamicin A₂ was purified by precipitation with ether from methanolic solution.

Mixture II: We separated the main components of this complicated mixture as follows: The first step was a repeated chromatography on Amberlite CG-50 Type-II resin with gradient elution by 0.08~0.12 N ammonium hydroxide. Compound II-1 /antibiotic G-418/ was isolated from the first enriched fractions by ion-exclusion chromatography on Dowex 1-X2 resin. The following active fractions were pooled and separated again by chromatography on Amberlite XE-69 resin. The elution was carried out by 0.08, 0.10 and 0.12 N ammonium hydroxide, successively. The final /0.12 N/ fractions of this chromatography contained compound II-4 /gentamicin A/ crystallized from ethanol-water. Fractions containing both compounds II-2 and II-3 /gentamicin X₂/ were pooled and rechromatographed on Amberlite CG-400 Type-II resin using ion-free water as eluent. Gentamicin X₂ was eluted first followed by

compound II-2. The final purification of components were achieved on Amberlite CG-50 Type-I resin columns by elution with 0.1 N ammonium hydroxide.

Mixture III: Crude compound III-1 was isolated from the first few fractions of repeated Amberlite CG-50 Type-II chromatography of this mixture with 0.12~0.14 N ammonium hydroxide and was purified by ion-exclusion chromatography on Dowex 1-X2 resin. The pooled and evaporated fractions, free from compound III-1 were chromatographed again on CM-Sephadex column eluted with 0.10, 0.12 and 0.14 N ammonium hydroxide, successively. The early fractions enriched in compound III-2 /garamine/ were subjected to ion-exclusion chromatography to obtain pure garamine. The final fractions containing mainly compound III-3 /gentamicin A₁/ were pooled and purified by repeated chromatography on CM-Sephadex.

Mixture IV: The fore run of the ion-exclusion chromatography of this mixture on Dowex 1-X2 resin contained apolar components /compounds IV-5 and IV-6/ and compounds IV-3 /antibiotic JI-20A/ and IV-4 /antibiotic JI-20B/. These fractions were pooled and separated by Amberlite CG-50 Type-II resin chromatography using 0.12, 0.14 and 0.16 N ammonium hydroxide as eluent. The fractions containing antibiotics JI-20A and JI-20B

were pooled and the mixture was separated by preparative TLC using system B as eluent. The main fractions of the ion-exclusion chromatography of mixture IV, containing IV-1 /gentamicin B/ and IV-2 /gentamicin B₁/ were chromatographed on CM-Sephadex column with 0.12 and 0.15 N ammonium hydroxide as eluent and gentamicins B and B₁ were separated.

Mixture V: This mixture was chromatographed on SP-Sephadex column. The successive elution with 0.12, 0.14, 0.16 and 0.18 N ammonium hydroxide gave compounds V-3 /gentamicin A₃/, V-1 /sisomicin/, and V-2 in order. Fractions containing each component were pooled and purified by repeated chromatography on Amberlite CG-50 Type-II columns using 0.15 N ammonium hydroxide as eluent.

Mixture VI: By repeated chromatography of mixture VI /gentamicin C complex/ on Amberlite CG-50 Type-II resin, we isolated pure gentamicin C₂ from the early fractions. The subsequent fractions were pooled and chromatographed on CM-Sephadex column with 0.15 and 0.18 N ammonium hydroxide as eluent. The 0.15 N eluate contains gentamicins C_{1a} and C₂, while the 0.18 N eluate contains practically pure gentamicin C₁. Subsequently to the gentamicin C_{1a}~C₂ mixture, which was separated by silica gel chromatography, a small amount of a new component was eluted /compound VI-4/. It is very similar in all

respects /molecular formula, PMR and mass spectra, bio-activity/ to gentamicin C₂, except the optical rotation / $[\alpha] +124^\circ$ /. We suppose that this material may be identical to gentamicin C_{2a}.

The isolation of mixture VI for purpose of industrial production of gentamicin C sulfate:

Eluate fractions 199-260 /62 l/ were pooled and evaporated in vacuo at 85°C until 30 % concentration /dry weight/. To this concentrated solution charcoal was added at room temperature, the mixture was stirred for 30 min, then filtered. The carbon cake was washed with water. The pH of the stirred, cooled filtrates was adjusted to 4.5 with 5 N sulfuric acid. The solution was decolorized again by carbon, stirred for 30 min, filtered and washed thoroughly with water. The filtrates thus obtained were poured while stirring into 10 volumes of puriss methanol. After a few hours standing at 5°C, the gentamicin C sulfate complex was filtered and washed with methanol. It was subsequently dried in vacuo at 50°C until constant weight. The yield of gentamicin sulfate corresponds to about 468 g of practically pure, anhydrous product, assay 640 mcg/mg. Ash content: about 0.1 %, volatiles: 2.8 %. Rotation: $[\alpha]_D^{25} = +112^\circ$ /1.0 % in water/. Components: C₁=34-36 %, C₂=45-49 %, C_{1a}=17-19 %. Over all yield calculated on gentamicin C of broth is 70.5 %.

Mixture VII: This rather complicated mixture containing at least 12 components was chromatographed first on Amberlite MB-69 resin with 0.16, 0.20, 0.30, 0.40 and 0.60 N ammonium hydroxide, successively. The first few fractions contained compound VII-4 /gentamine C₂/ which was purified by crystallization from ethanol-water. The following fractions were divided into three parts. Each submixture was chromatographed on CM-Sephadex columns and the separated components were purified by ion-exclusion chromatography on CAE-Sephadex or Dowex 1 x 2 columns. From the first submixture /0.20 0.30 N/ compounds VII-5 and VII-6 /gentamine C_{1a}/ were isolated. Chromatography of the second /0.40 N/ and third /0.60 N/ submixtures resulted in compounds VII-2 /gentamine C₁/ and VII-3, and compound VII-1, respectively.

REFERENCES

General literature

- E. Price, J. Godfrey, H. Kawaguchi: Adv. Appl. Microbiol. 18,
191 /1974/
Ann. Reports on Fermentation Processes Vol. 1. Edited by D. Perlman,
Chapt. 12. Aminoglycoside Antibiotics by Takashi Nara,
Academic Press /1977/

Original Paper

- M. Weinstein, G. Luedemann, E. Oden and G. Wagman: J. Med. Chem.
6, 463 /1963/

Strain and production patents

- Ger. Offen 2.145.395 /1972/
USP. 3.091.572 /1963/

Metabolism, physiology and influence of production

- A.A. Abu-Zeid, Indian J. Technol. 14, 513 /1976/
" J. Appl. Chem. Biotechnol. 24, 655 /1974/
" J. Appl. Chem. Biotechnol. 26, 318 /1976/
I.V. Gracseva, Antibiotiki 21, 102 /1976/
T.N. Laznikova, " 22, 102 /1977/
" " 22, 579 /1977/
" " 23, 499 /1978/
T.P. Krasnova, " 23, 12 /1978/

Genetics

A.V. Vladimirov, Antibiotiki 21, 1066 /1976/

Biosynthetic pathways

S.J. Daum, J. Ant. 30, 98 /1977/

B.K. Lee, J. Ant. 26, 728 /1973/

" " 27, 822 /1974/

" " 28, 163 /1975/

B.K. Lee, Antimicrob. Agents and Chemoth. 2, 151 /1976/

D. Rosi, J. Ant. 30, 88 /1977/

R.T. Testa, J. Ant. 29, 140 /1976/


Yu-Ming-Chen, Biochem. Biophys. Res. Commun. 77, 688 /1977/

Isolation and chemotherapy

J. Bérdy, J. Ant. 30, 945 /1977/



B-89



80.02.07